Chih-An Shih has a total of 63 co-authors. Here are the top co-authors by number of shared publications:

  • Ping-Ning Hsu

    Division of Gastroenterology, Department of Medicine, An Nan Hospital, China Medical University, Tainan, Taiwan

    8 shared publications
  • Deng-Chyang Wu

    Division of Gastroenterology, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan

    6 shared publications
  • Seng-Kee Chuah

    Division of Gastroenterology, Department of Internal Medicine Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine Kaohsiung Taiwan

    6 shared publications
  • I-Ting Wu

    Division of Gastroenterology, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan 709, Taiwan

    5 shared publications
  • Chang‐Bih Shie

    Division of Gastroenterology, Department of Internal Medicine Tainan Municipal An‐Nan Hospital, China Medical University Tainan Taiwan

    3 shared publications
  • Chao‐Hung Kuo

    Division of Gastroenterology, Department of Internal Medicine Kaohsiung Medical University Hospital Kaohsiung Taiwan

    3 shared publications

Latest Publications

  • Real‐world expectation in Helicobacter pylori eradication of patients in Taiwan—A pilot shared decision‐making survey

    by Yoen‐Young Chuah, Wei‐Yi Lei, Deng‐Chyang Wu, Hsi‐Chang Lee, Chang‐Bih Shie, Chao‐Hung Kuo, Kuan‐Yang Chen, Seng‐Kee Chuah, Chih‐An Shih, Feng‐Woei Tsay, et al.

    Helicobacter pylori infection remains a major cause of peptic ulcer disease and gastric malignancy. Increasing antibiotic resistance has reduced the efficacy of conventional triple therapy, prompting the introduction of alternative regimens. Shared decision‐making (SDM) can improve patient satisfaction and adherence, yet patient expectations in Taiwan remain under‐explored. A cross‐sectional, questionnaire‐based survey was conducted at three hospitals in southern Taiwan (Kaohsiung Medical University Hospital, An‐Nan Hospital, and Pingtung Christian Hospital) to assess patients' preferences and expectations for H. pylori eradication therapy. Eligible participants were adults who had received or were receiving eradication treatment. The questionnaire included items on demographics, preferred regimens, most‐concerned factors, and minimal acceptable eradication rates. Among 503 valid responses, most patients (80.3%) regarded eradication rate as the most important factor, followed by side effects (17.1%) and cost (2.6%). The mean minimal acceptable eradication rate was 90.2% (95% CI: 85.2–90.8). The 14‐day hybrid/reverse‐hybrid therapy was the most preferred regimen (72.6%), followed by 7‐day standard triple therapy (17.1%) and 14‐day bismuth quadruple therapy (4.6%). This first patient‐focused, multi‐center SDM survey in Taiwan revealed that most patients prioritize high eradication efficacy and favor the 14‐day hybrid/reverse‐hybrid regimen. These findings highlight a gap between patient and physician preferences and underscore the need to incorporate patient perspectives into routine clinical decision‐making and future guideline updates.

  • Bismuth–Amoxicillin–Vonoprazan Triple, Amoxicillin–Vonoprazan Dual, and Clarithromycin‐Based Triple Therapies for First‐Line Treatment of Helicobacter pylori Infection: A Multicenter, Open‐Label, Randomized Trial

    by Ping-I Hsu, Ming-Jen Sheu, Chien-Lin Chen, Wei-Yi Lei, Chih-An Shih, Feng-Woei Tsay, Sung-Shuo Kao, Chang-Bih Shie, Pei-Jui Wu, Chao-Hung Kuo, et al.

    Background: The eradication rate of amoxicillin–vonoprazan (AV) dual therapy for Helicobacter pylori ( H. pylori ) infection varies by region and is below 90% in both the United States and Taiwan. We recently added bismuth to this regimen, and the resulting bismuth–amoxicillin–vonoprazan (BAV) triple therapy achieved eradication rates ≥ 95% in Taiwan. Aims: To compare the efficacy and safety of 14‐day BAV triple therapy with AV dual therapy and clarithromycin–amoxicillin–rabeprazole (CAR) standard triple therapy as first‐line regimens for H. pylori eradication. Methods: In this multicenter, randomized, open‐label trial, adults with H. pylori infection were randomized (1:1:1) to receive one of the following 14‐day regimens: BAV triple therapy (tripotassium dicitrato bismuthate 300 mg four times daily, amoxicillin 750 mg four times daily, and vonoprazan 20 mg twice daily), AV dual therapy (vonoprazan 20 mg twice daily and amoxicillin 750 mg four times daily), or CAR standard triple therapy (rabeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily). Eradication was assessed by the 13 C‐urea breath test. The primary endpoint was eradication in the intention‐to‐treat population. Results: Between November 2023 and June 2025, 390 patients were enrolled. Intention‐to‐treat eradication rates were 93.8% with BAV therapy, 83.8% with AV therapy, and 83.1% with CAR therapy. BAV therapy was superior to both AV therapy (95% CI, 2.4%–17.6%; p = 0.010) and CAR therapy (95% CI, 3.0%–18.4%; p = 0.007). Per‐protocol eradication rates were 97.5%, 88.3%, and 88.0%, respectively; BAV therapy remained superior to AP therapy ( p = 0.010) and CAR therapy ( p = 0.05). Overall adverse event rates (10.8%, 8.5%, and 13.8%) were comparable. Amoxicillin resistance and clarithromycin resistance were identified as risk factors for eradication failure with BAV and CAR therapies, respectively. Conclusions: BAV triple therapy demonstrates superior efficacy compared with AV dual therapy and CAR triple therapy as first‐line treatment for H. pylori infection in Taiwan. This regimen represents a promising first‐line option that may obviate the need for routine clarithromycin‐resistance testing in regions where AV dual therapy yields suboptimal eradication rates.

  • Open Access

    Evolution of Amoxicillin-Based Mono-Antibiotic Regimens for Helicobacter pylori Eradication: From Ineffectiveness to Innovation—A Systematic Review

    by Chih-An Shih, I-Ting Wu, Deng-Chyang Wu, Wei-Yi Lei, Feng-Woei Tsay, Tzung-Jiun Tsai, Chung-Hung Tsai, Ya-Chi Wu, Wei-Chen Tai, Ping-I Hsu

    Mono-antibiotic therapy for Helicobacter pylori (H. pylori) infection minimizes unnecessary antibiotic exposure, reduces disruption of the gut microbiota, and lowers the risk of multidrug resistance. Although resistance of H. pylori to amoxicillin remains extremely low (H. pylori. All regimens lasted 14 days and were studied in clinical trials published between 1 October 2014, and 1 October 2025. The pooled intention-to-treat and per-protocol eradication rates for each regimen were as follows: Regimen 1: Regular-dose amoxicillin + high-dose proton pump inhibitor (PPI): 84.7% (83/98) and 84.7% (83/98); Regimen 2: High-dose amoxicillin + high-dose PPI: 85.3% (3709/4347) and 89.9% (3692/4109); Regimen 3: Regular-dose amoxicillin + high-dose potassium-competitive acid blocker (PCAB): 86.0% (901/1048) and 91.2% (888/974); Regimen 4: High-dose amoxicillin + high-dose PCAB: 88.2% (1771/2009) and 93.5% (1720/1839); Regimen 5: Regular-dose amoxicillin + high-dose PCAB + bismuth: 84.9% (327/385) and 91.3% (327/358); Regimen 6: High-dose amoxicillin + high-dose PCAB + bismuth: 95.8% (115/120) and 98.4% (115/117). In conclusion, potent acid inhibition, escalation of amoxicillin dosage, and incorporation of bismuth can transform amoxicillin mono-antibiotic therapy from an ineffective approach into a highly effective eradication regimen for H. pylori infection.


  • The efficacy and safety of high‐dose amoxicillin‐bismuth‐potassium competitive acid blocker therapy for Helicobacter pylori infection—A pilot study

    by Ping‐I Hsu, Deng‐Chyang Wu, Seng‐Kee Chuah, Kai‐Chun Yang, Chao‐Hung Kuo, Chia‐Long Lee, Chih‐An Shih, I‐Ting Wu, Chang‐Bih Shie, Feng‐Woei Tsay

    Recent developments in Helicobacter pylori ( H. pylori ) treatment have highlighted the rising resistance to clarithromycin. Conversely, amoxicillin resistance remains relatively low in both first‐line and rescue treatments. Evidence has shown that the effectiveness of high‐dose amoxicillin/proton pump inhibitor dual therapy varies in different countries. The effectiveness of combining high‐dose amoxicillin with potassium‐competitive acid blocker (PCAB) and bismuth as a mono‐antibiotic strategy for H. pylori eradication remains to be determined. To assess the efficacy and safety of a 14‐day regimen combining bismuth, high‐dose amoxicillin, and PCAB (Bap therapy) as both first‐line and rescue treatment for H. pylori infection, and to identify the factors that affect the outcome of this novel therapeutic approach. We conducted a retrospective cohort study of patients with H. pylori infection treated with Bap therapy from January 2021 to March 2024 across four hospitals in Taiwan. The regimen consisted of tripotassium dicitrato bismuthate (300 mg four times daily), high‐dose amoxicillin (750 mg four times daily), and vonoprazan (20 mg twice daily) for 14 days. Patients returned in the second week to assess drug adherence and adverse events. Post‐treatment H. pylori status was assessed at least 4 weeks following Bap therapy. Fifty‐one patients receiving Bap therapy as either first‐line ( n = 45) or rescue treatment ( n = 6) were analyzed. Eradication rates in first‐line treatment were 95.6% (95% confidence interval [CI]: 89.6%–100.0%), 97.7% (95% CI: 93.3%–100.0%), and 100.0% in intention‐to‐treat, modified intention‐to‐treat, and per‐protocol analyses, respectively. For rescue therapy, the corresponding eradication rates were all 100%. Adverse event rates were 6.7% for first‐line and 0% for rescue treatments, with adherence rates of 95.6% and 100%, respectively. Univariate analysis indicated significantly lower eradication rates in patients with poor drug adherence (50% vs. 100%; p = .040), while factors such as smoking, alcohol consumption, clarithromycin, and metronidazole resistance did not influence outcomes. The 14‐day Bap therapy demonstrates high efficacy and safety for both first‐line and rescue treatments of H. pylori infection, making it a potential standard treatment option for H. pylori eradication. This study underscores the importance of adherence to therapy and warrants further research to validate the effectiveness of this mono‐antibiotic approach across different lines of treatment for H. pylori infection.


  • Vonoprazan High-Dose Dual, Vonoprazan Triple, and Rabeprazole Reverse Hybrid Therapies for First-Line Treatment of Helicobacter pylori Infection: A Multicenter Randomized Trial

    by Ping-I Hsu, Chien-Lin Chen, Chih-An Shih, Kuan-Yang Chen, Wei-Chen Tai, Seng-Kee Chuah, Chia-Long Lee, Feng-Woei Tsay, Jyh-Chin Yang, Wei-Yi Lei, et al.

    INTRODUCTION: The aim of this study was to compare the efficacy of 14-day vonoprazan high-dose dual, vonoprazan triple, and rabeprazole reverse hybrid therapies for the first-line treatment of Helicobacter pylori infection. METHODS: In the multicenter, randomized, open-label trial, we consecutively recruited adult H. pylori -infected patients from 6 centers in Taiwan. Subjects were randomly assigned (1:1:1) to 14-day vonoprazan high-dose dual, vonoprazan triple, or rabeprazole reverse hybrid therapy. Eradication status was determined by 13 C-urea breath test. The primary outcome was the eradication rate of H. pylori assessed in the intention-to-treat population. RESULTS: Between December 2021 and April 2024, 906 patients were recruited. The eradication rates were 83.8% (253/302) for vonoprazan high-dose dual therapy, 90.1% (272/302) for vonoprazan triple therapy, and 89.1% (271/302) for rabeprazole reverse hybrid therapy in intention-to-treat analysis. Vonoprazan high-dose dual therapy was inferior to both vonoprazan triple (95% confidence interval −11.5% to −1.1%; P = 0.022) and rabeprazole reverse hybrid therapies (95% confidence interval −10.7% to 0.1%; P = 0.031). There were no significant differences in the overall proportions of patients experiencing adverse events among vonoprazan high-dose dual, vonoprazan triple, and rabeprazole reverse hybrid groups (10.3%, 15.2%, and 15.6%, respectively). Body weight ≥60 kg, clarithromycin resistance, and poor drug adherence were independent risk factors predicting eradication failure for the 3 corresponding therapies, with odds ratios of 3.2 (1.3–7.5), 4.8 (1.2–18.9), and 14.8 (2.8–78.8), respectively. DISCUSSION: Vonoprazan triple therapy and rabeprazole reverse hybrid therapy are preferable to vonoprazan dual therapy for the first-line treatment of H. pylori infection.


  • Open Access

    Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan for Helicobacter pylori Infection: A Systematic Review

    by Chih-An Shih, Deng-Chyang Wu, Chang-Bih Shie, Ping-I Hsu

    Due to the increasing prevalence of antimicrobial resistance, the efficacy of standard triple therapy for Helicobacter pylori (H. pylori) infection has declined, with eradication rates now falling below 80% in most countries. Although bismuth quadruple therapy and concomitant therapy are advised in regions with high clarithromycin resistance, these treatments commonly cause frequent adverse events and require the use of two or three antibiotics. This review article evaluates the effectiveness of 14-day mono-antibiotic therapies for H. pylori infection through randomized controlled trials conducted from 1 October 2014 to 1 October 2024. The pooled eradication rates for 14-day high-dose amoxicillin/proton pump inhibitor (PPI) dual therapies were 86.1% (3335/3875; 95% confidence interval (CI): 85.1–87.2%) by intention-to-treat (ITT) analysis and 87.3% (3232/3702; 95% CI: 86.2–88.4%) by per-protocol (PP) analysis. For 14-day high-dose amoxicillin/vonoprazan dual therapies, the rates were 87.4% (1085/1241; 95% CI: 85.5–89.2%) by ITT and 93.0% (1044/1124; 95% CI: 91.5–94.5%) by PP. In the penicillin-allergic population, 14-day tetracycline/vonoprazan dual therapy showed eradication rates of 92.0% (138/150) by ITT and 95.1% (135/142) by PP. In conclusion, 14-day tetracycline/vonoprazan dual therapy presents an effective option for eradicating H. pylori in patients allergic to penicillin. For those without a penicillin allergy, first-line treatments can include 14-day mono-antibiotic regimens, such as high-dose amoxicillin/PPI dual, high-dose amoxicillin/vonoprazan dual, and tetracycline/vonoprazan dual therapies.


  • Risk factors for symptom relapse in patients with Los Angeles Grade A/B erosive esophagitis

    by Chih‐An Shih, Seng‐Kee Chuah, Ping‐I Hsu, Ching‐Liang Lu, Sung‐Shuo Kao, Wei‐Chen Tai, I‐Ting Wu, Kun‐Feng Tsai, Wen‐Wei Huang, Sheng‐Yeh Tang, et al.

    Recurrence of reflux symptoms following discontinuing proton pump inhibitor therapy is a common problem in the treatment of gastroesophageal reflux disease. We aim (1) to examine the cumulative 12‐week incidence of symptom relapse following 8‐week proton pump inhibitor therapy in patients with Los Angeles grade A/B erosive esophagitis and (2) to search the risk factors predicting symptom relapse in the treatment of erosive esophagitis. From June 2010 to May 2019, patients with Los Angeles Grade A/B erosive esophagitis receiving esomeprazole therapy (40 mg qd) for 8 weeks followed by complete symptom resolution were included in this study. Subjects received on‐demand esomeprazole treatment for 12 weeks and underwent prospective follow‐up for reflux symptoms. 12‐week cumulative incidence of symptom relapse was assessed, and predictive risk factors for symptom relapse were determined by multivariate analysis. 219 patients with Los Angeles Grade A/B erosive esophagitis who achieved complete symptom resolution following 8‐week esomeprazole therapy were enrolled. During the 12‐week follow‐up period, 110 patients (50.2%) developed symptom relapse. Univariate analysis showed that symptom relapse was significantly associated with advanced age, smoking, and the presence of heartburn (p = .003, .015, and .042, respectively). Multivariate analysis with stepwise logistic regression showed that only advanced age (95% confidence interval [CI]: 1.45–5.15) and smoking (95% CI: 1.30–6.58) were independent factors predicting symptom relapse with odds ratios of 2.74 and 2.92, respectively. The 12‐week cumulative incidence of symptom relapse following initial proton pump inhibitor treatment in patients with Los Angeles grade A/B erosive esophagitis is 50.2%. Advanced age and smoking are independent risk factors predicting symptom relapse following treatment in patients with mild erosive esophagitis.


  • Open Access

    Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users

    by Jui-Ting Hsu, Ping-I Hsu, Chang-Bih Shie, Seng-Kee Chuah, I-Ting Wu, Wen-Wei Huang, Sheng-Yeh Tang, Kun-Feng Tsai, Li-Fu Kuo, Supratip Ghose, et al.

    Background and Objectives: Hepatitis C virus (HCV) is a major cause of liver disease worldwide. People who inject drugs (PWIDs) constitute the majority of patients with HCV infection in the United States and Central Asia. There are several obstacles to treating HCV infection in PWIDs because PWIDs are often accompanied by concurrent infection, low compliance, substance abuse, and risky behavior. The aim of the study is to compare the efficacies of direct-acting antiviral (DAA) therapy for HCV infection in PWIDs and those without opioid injection. Materials and Methods: In this retrospective cohort study, we included 53 PWIDs with HCV infections treated on site in a methadone program and 106 age- and sex-matched patients with HCV infections who had no history of opioid injection (ratio of 1:2). All eligible subjects received anti-HCV treatment by DAA agents in our hospital from March 2018 to December 2020. The charts of these patients were carefully reviewed for demographic data, types of DAA agents, and treatment outcomes. The primary outcome measure was sustained virological response (SVR). Results: PWIDs and non-drug users had different HCV genotype profiles (p = 0.013). The former had higher proportions of genotype 3 (18.9% vs. 7.5%) and genotype 6 (24.5% vs. 14.2%) than the latter. The two patient groups had comparable rates of complete drug refilling (100.0% vs. 91.1%) and frequency of loss to follow-up (3.8% vs. 0.9%). However, PWIDs had a lower SVR rate of DAA treatment than non-drug users (92.2% vs. 99.0%; p = 0.04). Further analysis showed that both human immunodeficiency virus (HIV) coinfection and history of PWID were risk factors associated with treatment failure. The subjects with coinfection with HIV had lower SVR rates than those without HIV infection (50.0% vs. 96.5%; p = 0.021). Conclusions: PWIDs with HCV infections have higher proportions of HCV genotype 3 and genotype 6 than non-drug users with infections. DAA therapy can achieve a high cure rate (>90%) for HCV infection in PWID, but its efficacy in PWID is lower than that in non-drug users.


  • Open Access

    Pseudomelanosis duodeni in a female adult with chronic renal failure

    by Wei‐Chih Sun, Feng‐Woei Tsay, Kwok‐Hung Lai, Ping‐I Hsu, Chih‐An Shih

    Summary: Pseudomelanosis duodeni is a rare endoscopic finding that manifests as dark speckled spots in the duodenum. It is considered a benign condition and is associated with certain diseases and the use of certain medications. This study reports a case of a 74‐year‐old woman, with end‐stage renal disease under maintenance hemodialysis, hypertension under regular medical control, iron deficiency anemia under oral iron supplement, and progressive anemia with suspicious occult gastrointestinal bleeding. Upper gastrointestinal endoscopy revealed multiple tiny brownish‐black pigmentation throughout the proximal second portion of the duodenum. The histopathological examination showed pigment‐laden macrophages with positive iron stain and negative melanin stain in the lamina propria of the mucosal villi.